Zhen Su

SVP, Head of U.S. and Global Oncology Franchise


Zhen Su, MD, MBA, is the SVP, Head of U.S. and Global Oncology Franchise. In this role, Dr. Su oversees all commercial operations for the franchise in the US and also global commercial efforts for our oncology therapies.

A physician executive with more than 20 years of experience, Dr. Su held roles at a number of academic institutions – including at Duke University and University of Florida, where he led early clinical development in Immuno-Oncology as a faculty member – before joining the biopharmaceutical industry.

Within EMD Serono, he previously held the position of Chief Medical Officer for EMD Serono, working with the medical, development and regulatory teams to lead EMD Serono’s medical strategy, clinical presence and scientific leadership in the US. Before joining EMD Serono, he held leadership roles in general management, clinical development and medical affairs at Sanofi and GlaxoSmithKline.

Dr. Su earned his MD from the Technical University of Dresden, Germany and completed his MBA training at the University of Toronto, Canada.


You have accessed https://www.emdserono.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website. 

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement